News
Important Only
Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With Ipf
May 27 (Reuters) - REIN THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN RENEW PHASE 2 TRIAL OF LTI-03 IN PATIENTS WITH IPFREIN THERAPEUTICS INC: TOPLINE INTERIM DATA FROM RENEW IS EXPECTED IN FIRST HALF OF 2026Reuters
Tue, May 27
Imaflex Q1 EPS CAD 0.01
May 27 (Reuters) - Imaflex Inc IFX.V:IMAFLEX Q1 EPS CAD 0.01IMAFLEX Q1 EBITDA CAD 2.123 MILLIONIMAFLEX Q1 NET INCOME CAD 264 THOUSANDIMAFLEX Q1 REVENUE CAD 28.923 MILLIONIMAFLEX Q1 GROSS PROFIT CAD 4.725 MILLIONIMAFLEX Q1 BASIC EPS CAD 0.01IMAFLEX Q1 GROSS MARGIN 16.3%Reuters
Tue, May 27
REFILE-ANALYSIS-US climate pullback threatens planned debt-for-nature deals
US Development Finance Corporation support in questionAngola, Zambia swaps among those impacted, sources say Angola says DFC more open to a development-swap dealBy Marc Jones and Virginia Furness LONDON, May 22 (Reuters) - Billions of dollars of debt deals aimed at protecting vital ecosystems fro...Reuters
Tue, May 27
FACTBOX-Foreign companies eye US expansion to lessen fallout from tariffs
May 27 (Reuters) - Some non-U.S. companies have said they are looking at expanding their presence or setting up shop in the United States to mitigate the impact of President Donald Trump's tariffs.Below are some of the plans flagged by those companies.BARRY CALLEBAUT BARN.SThe chocolate maker is...Reuters
Tue, May 27
Ituran Announces New OEM Agreement With Stellantis In South America
May 27 (Reuters) - Ituran Location and Control Ltd ITRN.O:ITURAN ANNOUNCES NEW OEM AGREEMENT WITH STELLANTIS IN SOUTH AMERICAITURAN LOCATION AND CONTROL LTD - CONTRACT COVERS MULTIPLE COUNTRIES IN SOUTH AMERICA FOR MULTI-YEAR PERIODReuters
Tue, May 27
Ocugen Announces Rare Pediatric Disease Designation Granted For Ocu410st—Modifier Gene Therapy For The Treatment Of Stargardt Disease
May 27 (Reuters) - Ocugen Inc OCGN.O:OCUGEN ANNOUNCES RARE PEDIATRIC DISEASE DESIGNATION GRANTED FOR OCU410ST—MODIFIER GENE THERAPY FOR THE TREATMENT OF STARGARDT DISEASEOCUGEN INC: PLANS TO INITIATE PHASE 2/3 PIVOTAL CONFIRMATORY TRIAL IN FEW WEEKS WITH TARGET BLA IN 2027Reuters
Tue, May 27
Gilat Receives Over $25 Million In Orders For Its Multi-Orbit Satellite Solutions
May 27 (Reuters) - Gilat Satellite Networks Ltd GILT.TA:GILAT RECEIVES OVER $25 MILLION IN ORDERS FOR ITS MULTI-ORBIT SATELLITE SOLUTIONSGILAT SATELLITE NETWORKS LTD - DELIVERIES SCHEDULED THROUGHOUT 2025 AND 2026Reuters
Tue, May 27
Circle Internet Group - IPO Price Expected Between $24.00 And $26.00 Per Share - SEC Filing
May 27 (Reuters) - CIRCLE INTERNET GROUP INC - IPO PRICE EXPECTED BETWEEN $24.00 AND $26.00 PER SHARE - SEC FILINGCIRCLE INTERNET GROUP INC - FILES FOR IPO OF 24 MILLION CLASS A COMMON STOCK - SEC FILINGSource text: [ID:n0001193125-25-126208]Further company coverage: [ ]Reuters
Tue, May 27
Juri Biosciences & Epimab Biotherapeutics Enter Into Worldwide Licensing Agreement For Klk2-Directed T-Cell Engager In Metastatic Prostate Cancer
May 27 (Reuters) - JURI BIOSCIENCES & EPIMAB BIOTHERAPEUTICS ENTER INTO WORLDWIDE LICENSING AGREEMENT FOR KLK2-DIRECTED T-CELL ENGAGER IN METASTATIC PROSTATE CANCERTCG LABS SOLEIL: UNDER AGREEMENT, EPIMAB IS ELIGIBLE TO RECEIVE UP TO $210 MILLIONFurther company coverage: [ ]Reuters
Tue, May 27
